Skip to content

Effects of clinical pharmacist interventions on the secondary prevention in the ischemic stroke patients

Effects of clinical pharmacist interventions on the secondary prevention in the ischemic stroke patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002127
Enrollment
Unknown
Registered
2012-04-26
Start date
2012-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Control group:Traditional medication education for discharged patients
Treatment group:Individual pharmaceutical care for the discharged patients by clinical pharmacists

Sponsors

Second Affiliated Hospital Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The first attack of cerebral infarction patients in line with the ICD-10 acute cerebral infarction diagnostic criteria; 2. The TOAST types are include of large-artery atherosclerosis (embolus / thrombosis) and small-vessel occlusion (lacune); 3. Aged 35 to 75 years; 4. Within 14 days - 3 months after the first onset, there are symptoms of cerebral infarction which was confirmed by neuroimaging procedure to rule out hemorrhagic stroke; 5. Written informed consent by patients or their family numbers; 6. There is more than one risk factor of the cerebrovascular disease which can be intervened.

Exclusion criteria

Exclusion criteria: 1. Massive cerebral infarction or coma; Modified Rankin Scale (mRS) score> 4; Water swallow test score >=4; There are other reasons that can not take medication on time; 2. There is an angioplasty in the past for intracranial arterial stenosis; 3. Pregnant or lactating women; 4. Allergic; 5. The TOAST types are include of cardioembolism stroke, other determined aetiology or stroke of undetermined aetiology; 6. Can not complete follow-up of one year being of concomitant diseases such as severe heart disease, cardiac insufficiency, hepatosis, renal inadequacy, respiratory failure and malignancy. Gastrointestinal disorders that affecting drug absorption seriously. Coagulation disorders or previous with systemic hemorrhagic disease. Previous with cerebral hemorrhage; 7. It is concerned by researchers that are not suitable for clinical trials being of other reasons.

Design outcomes

Primary

MeasureTime frame
Recurrence of stroke;Myocardial infarction;Vascular death;readmission for acute ischemia;

Secondary

MeasureTime frame
Medication compliance;Smoking cessation;Exercise;Alcohol consumption;Body weight;Blood pressure;Serum glucose;Serum lipids;Adverse drug reaction;

Countries

China

Contacts

Public ContactDai Haibin
haibindai@163.com+86 13600527604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026